The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
VOYAGER (KSCC1902): A single-arm, multicenter, phase II study of early induction of nivolumab during second-line treatment with taxane ± ramucirumab for advanced gastric or gastro-esophageal junction cancer.
 
Hiroo Katsuya
Honoraria - Chugai Pharma
 
Akitaka Makiyama
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Lilly Japan
 
Tomomi Kashiwada
Speakers' Bureau - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda
 
Yudai Shinohara
No Relationships to Disclose
 
Qingjiang Hu
No Relationships to Disclose
 
Satoshi Otsu
No Relationships to Disclose
 
Akira Yoneda
No Relationships to Disclose
 
Yasunori Emi
No Relationships to Disclose
 
Nobuya Ishibashi
No Relationships to Disclose
 
Eto Kojiro
No Relationships to Disclose
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Mototsugu Shimokawa
No Relationships to Disclose
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Hiroshi Saeki
No Relationships to Disclose
 
Masaki Mori
No Relationships to Disclose